Bryan Johnson· Author
Results of “BELIEVE” trial redefine the rules for GLP1RA therapies: lose fat, keep muscles. + Trial tested semaglutide (Wegovy) with Bimagrumab, a novel monoclonal antibody treatment treatment for preserving muscle
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Results of “BELIEVE” trial redefine the rules for GLP1RA therapies: lose fat, keep muscles. + Trial tested semaglutide (Wegovy) with Bimagrumab, a novel monoclonal antibody treatment treatment for preserving muscle
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
Unveiled on 23 June at the American Diabetes Association’s 85th Scientific Sessions, the Phase 2b BELIEVE trial (NCT05616013) enrolled 507 adults with obesity/over-weight to test IV Bimagrumab, with or without weekly semaglutide, against each agent alone and placebo.